Summit Therapeutics (NASDAQ:SMMT) vs. Ainos (NASDAQ:AIMD) Head to Head Survey

Summit Therapeutics (NASDAQ:SMMT) and Ainos (NASDAQ:AIMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Valuation & Earnings

This table compares Summit Therapeutics and Ainos”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08 billion	($1.60)	-8.76
Ainos	$18,111.00	898.95	-$14.77 million	($2.89)	-0.66

Ainos has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Summit Therapeutics has a beta of -1.32, meaning that its share price is 232% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Summit Therapeutics and Ainos, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2	6	8	1	2.47
Ainos	1	0	0	0	1.00

Summit Therapeutics currently has a consensus target price of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Ainos.

Profitability

This table compares Summit Therapeutics and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Ainos	-11,912.10%	-160.55%	-62.29%

Insider and Institutional Ownership

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Summit Therapeutics beats Ainos on 8 of the 14 factors compared between the two stocks.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.